Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

shankar besta

  • Home
  • Author: shankar besta

Viking Therapeutics’ obesity drug could become direct competitor to Eli Lilly’s tirzepatide, says GlobalData

The obesity market continues to expand, but therapeutic options remain limited and shortages in supply continue. This creates a significant opportunity for new entrants. Numerous companies are exploring potential breakthrough mechanisms of action beyond GLP-1R agonists, while others are focusing on the synergistic effects of targeting multiple receptors to enhance the benefits of GLP-1R agonists. […]
Read more

Majority of top 20 biopharma firms see revenue growth in 2023 despite 1.6% fall in aggregate revenue, reveals GlobalData

The biopharmaceutical industry experienced varied revenue shifts in 2023, with significant success for companies with obesity drugs. Over half (13) of the top 20 publicly traded global innovative biopharmaceutical companies witnessed revenue growth in 2023, despite an overall 1.6% decline in aggregate revenue to $816 billion from 2022 to 2023, reveals GlobalData, a leading data […]
Read more

Influencers on ‘X’ anticipate SearchGPT to revolutionize search engine market with AI-driven innovations, reveals GlobalData

The recent unveiling of OpenAI’s SearchGPT for an artificial intelligence (AI)-driven search experience, featuring real-time information summarization, interactive follow-up questions, and visual answers, has garnered widespread attention. The unveiling has sparked considerable discussion among influencers on social media platform ‘X’ in the fourth week of July, emphasizing its potential to revolutionize the search engine landscape, […]
Read more

Gilead’s lenacapavir holds greater potential in reducing HIV incidence than currently marketed drugs, says GlobalData

At the 25th International AIDS Conference (AIDS 2024) that took place from July 22-26 in Munich, Germany, Gilead presented full efficacy and safety results for its Phase III PURPOSE 1 HIV prevention trial for lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor. Lenacapavir demonstrated zero infections and 100% efficacy, as well as superior prevention of HIV […]
Read more

Phase III post-marketing commitment study data paves way for usage of Paratek’s Nuzyra in other indications, says GlobalData

Paratek Pharmaceuticals has announced positive topline efficacy and safety data from a global, Phase III post-marketing commitment study of its novel antibiotic, a next-generation tetracycline, Nuzyra (omadacycline). In a study of 670 adults with moderate to severe community-acquired bacterial pneumonia (CABP), Nuzyra was found to be generally safe and well-tolerated. The drug met both primary […]
Read more

NewAmsterdam’s obicetrapib holds potential to become first CETP inhibitor to advance to clinical practice, says GlobalData

NewAmsterdam Pharma has completed the enrollment of 407 patients in the pivotal Phase III TANDEM clinical trial evaluating obicetrapib in combination with ezetimibe in patients with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD). Obicetrapib has demonstrated strong tolerability in more than 800 patients with elevated lipid levels in NewAmsterdam’s clinical trials to date. […]
Read more

Healthcare’s growing reliance on tech demands robust cybersecurity measures, says GlobalData

The healthcare industry is increasingly dependent on digital technologies and interconnected medical devices, which has heightened the importance of cybersecurity. Given the growing dependence on technology in healthcare, there is a pressing need for increased spending on medical device security, a thorough understanding of the implications of expanding interconnectivity, and the need for robust cybersecurity […]
Read more

Mabwell leads development of new generation nectin-4 ADCs in China for triple-negative breast cancer, says GlobalData

Mabwell (Shanghai) Bioscience recently received the National Medical Products Administration (NMPA) approval for its 9MW2821, a novel nectin-4 targeting ADC (antibody-drug conjugate), to enter Phase II clinical trial in China. The preliminary clinical results of the Phase I/II study presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting demonstrated promising efficacy in […]
Read more
1 … 68 69 70 71 72 … 136